BRIEF—CDR-Life earns milestone payment under deal with Boehringer

Swiss biopharma firm CDR-Life today announced that Germany’s Boehringer Ingelheim has selected an antibody treatment fragment-based therapeutic candidate for advancement to the next phase of development under the existing, May 2020, agreement between the companies for the discovery and development of novel therapies for the treatment of geographic atrophy, a blinding retinal disease, triggering an undisclosed milestone payment from Boehringer Ingelheim to CDR-Life.

“We have had an incredibly productive and seamless research collaboration between Boehringer Ingelheim and CDR-Life, and together taken an important step towards identifying a candidate with the potential to address the unmet medical need posed by this devastating disease,” said Christian Leisner, chief executive Oat CDR-Life.

Terms of Boehringer and CDR-Life’s cllaboration

Under the terms of the agreement, Boehringer Ingelheim will receive an exclusive, worldwide license to develop certain compounds based on CDR-Life´s technology against a specific target and will be responsible for global development and commercialization.

CDR-Life is eligible to receive up to 474.5 million Swiss francs ($520 million) in upfront and success-based milestone payments, as well as research funding and royalties on sales of novel therapies for the treatment of geographic atrophy triggering an undisclosed milestone payment from Boehringer Ingelheim to CDR-Life.